Trial | Survey identified | ||||||
---|---|---|---|---|---|---|---|
Trial/Country | Trial details | Cites 25OHD Survey (S)/ Systematic Review (SR) | Recruitment started | Survey Date | Group surveyed | 25OHD[mean/median(SD)] (nmol/L)/Assay | Survey Referencea |
D-Health Australia | N = 21,315, 5y 60,000 IU D3 monthly v placebo Men/women 60-84y ACTRN12613000743763 | S:Yes Tran 2012 pilot PSR:Yes ASR:Yes | 2014 | 2010–1 | Men and women | 41.7 (13.5) | Tran 2012 [87] Waterhouse 2015 [88] |
Mean age 72y | Liaison | ||||||
 |  |  | 2011–2 | Men and Women | 68.9/69.8/68.6 | Australian health survey 2011–2 [89] | |
55-64y/65-74y/>75y | LCMS/MS | ||||||
DO-HEALTH 5 countries in Europe | N = 2152, 3y 2000 IU/d D3 v placebo Men/women ≥70y NCT01745263 | S:NDA PSR:NDA ASR: NDA | 2012 |  |  |  |  |
FIND Finland | N = 2495, 5y 1600 IU/d D3 v 3200 IU/d D3 v placebo Men ≥60y, women ≥65y NCT01463813 | S:Yes Hurskainen 2012 PSR:No ASR:Yes | 2012 | 1998- 2001 | Men and women | 43.4 (17.6) | Hurskainen 2012 [90] |
Mean age 62.9y | HPLC | ||||||
Recruitment stopped early had aimed for 18,000 |  |  | 2003–5 | Men and women | 64.8 (17.4) | Salminen 2015 [91] | |
Mean age 73.5y | IDS | ||||||
 |  |  | 2011–2 | Men and women | 58.6 (9.3) | Carlberg 2013 [92] | |
Mean age 66.6y | HPLC | ||||||
TIPS-3 10 countries in Africa, Asia, South/ North America | N = 5000, 5y 60,000 IU D3 3 monthly v placebo Men ≥55y, women ≥60y NCT01646437 | S:NDA PSR:NDA ASR:NDA | 2012 |  |  |  |  |
VIDAL UK | N = 1600, 2y 100,000 IU D3 monthly v placebo Men and women 65-84y ISRCTN46328341 Feasibility trial. Full trial (n = 20,000) not funded | S:Yes Hirani 2005 PSR:Yes ASR:Yes | 2012 | 2000 | Private households | Diasorin | Hirani 2005 [93] |
Men 65-79y/80+ | 58 (27)/48 (24) | ||||||
Women 65-79y/80+ | 49 (25)/45 (20) | ||||||
Institutions | Â | ||||||
Men 65-79y/80+ | 40 (24)/37 (20) | ||||||
Women 65-79y/80+ | 37 (18)/37 (19) | ||||||
VITAL US | N = 25,874, 5y 2000 IU/d D3 v placebo Men ≥50y, women ≥55y NCT01169259 | S:Yes Looker 2002 PSR:Yes ASR:Yes | 2010 | 1988–1994 | Winter, lower latitude | Diasorin | Looker 2002 [94] |
Women 40-80y+ | 61.6–59.6 | ||||||
Men 40-80y+ | 70.6–68.7 | ||||||
Summer, higher latitude | Â | ||||||
Women 40-80y+ | 68.6–61.8 | ||||||
Men 40-80y+ | 78.8–69.5 | ||||||
 |  |  | 2005–2010 | Men and women | LC-MS/MS equivalent | Schleicher 2016b [79] | |
40-59y | 60.1–68.7 | ||||||
≥60y | 59.4–72.6 | ||||||
 |  |  | 1988–1994 | Men and women | LC-MS/MS equivalent | Schleicher 2016b [79] | |
40-59y | 60.1 (58.7,61.5) | ||||||
≥60y | 58.4 (57.4,59.5) | ||||||
CAPS US | N = 2303, 5y 2000 IU D3 and 1500 mg calcium daily v calcium Women ≥55y NCT01052051 | S:NDA PSR:NDA ASR:NDA | 2009 | 2005–2010 | Men and women | LC-MS/MS equivalent | Schleicher 2016b [79] |
40-59y | 60.1–68.7 | ||||||
≥60y | 59.4–72.6 | ||||||
All females | 60.9–69.1 |